financetom
Business
financetom
/
Business
/
Accolade Shares Rise After Fiscal Q2 Net Loss Narrows, Revenue Rises; Sets Q3 Guidance, Reiterates 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Accolade Shares Rise After Fiscal Q2 Net Loss Narrows, Revenue Rises; Sets Q3 Guidance, Reiterates 2025 Outlook
Oct 11, 2024 12:05 AM

12:56 PM EDT, 10/08/2024 (MT Newswires) -- Accolade's (ACCD) shares were up more than 7% in recent trading on Tuesday after the company reported a fiscal Q2 net loss of $0.30 per diluted share, narrower than a loss of $0.43 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.44.

Revenue for the quarter ended Aug. 31 was $106.4 million, up from $96.9 million a year earlier. Analysts surveyed by Capital IQ expected $105 million.

The company said it expects Q3 revenue between $104 million and $107 million. Analysts polled by Capital IQ expect $108.6 million.

The company reiterated its fiscal 2025 revenue outlook between $460 million and $475 million. Analysts surveyed by Capital IQ expect $466.5 million.

Price: 4.30, Change: +0.33, Percent Change: +8.19

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Supreme Court Reportedly Rejects Musk's Bid to Challenge Agreement with SEC
--Supreme Court Reportedly Rejects Musk's Bid to Challenge Agreement with SEC
Apr 29, 2024
10:47 AM EDT, 04/29/2024 (MT Newswires) -- Price: 188.69, Change: +20.40, Percent Change: +12.12 ...
Annovis' Alzheimer's treatment helps improve cognition in trial
Annovis' Alzheimer's treatment helps improve cognition in trial
Apr 29, 2024
April 29 (Reuters) - Annovis Bio ( ANVS ) said on Monday its Alzheimer's treatment showed significantly higher improvement in cognition in patients during a mid-stage trial. The company's drug buntanetap works by decreasing the production of amyloid beta protein, believed to be a hallmark of Alzheimer's, from the brain. Annovis plans to conduct a late-stage trial based on results...
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
Apr 29, 2024
10:51 AM EDT, 04/29/2024 (MT Newswires) -- Sight Sciences ( SGHT ) said Monday it has received a jury trial verdict of $34 million related to the patent-infringement case it filed in September 2021 against Alcon ( ALC ) in the US District Court for the District of Delaware. The eyecare technology company said that it has asserted that Alcon's...
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
Apr 29, 2024
Monday, Addex Therapeutics ( ADXN ) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.  The company is collaborating with Johnson & Johnson’s  Janssen Pharmaceuticals Inc. The Phase 2 study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved